Posted on 11/2/20
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the third . . .
Posted on 11/2/20
Novavax Plans Major Expansion In Montgomery County, Commits To At Least 400 New Jobs
Growing vaccine developer is expanding into new R&D, manufacturing facility in GaithersburgNovavax, a clinical stage vaccine company that is currently developing a COVID-19 vaccine, has announced . . .
Posted on 11/2/20
Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results
BOSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare . . .
Posted on 11/2/20
ProPhase Labs Completes Acquisition of CLIA Accredited Lab
DOYLESTOWN, Pennsylvania, Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has completed . . .
Posted on 11/2/20
Rexahn Pharmaceuticals Stockholder Approved Merge with Ocuphire Pharma
ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) announced today that at its special meeting of stockholders held on November 2, 2020, . . .
Posted on 11/2/20
Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced financial results for the third quarter 2020 and provided a corporate . . .
Posted on 11/2/20
Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, . . .
Posted on 11/2/20
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
WALTHAM, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central . . .
Posted on 11/2/20
Date Is Set for Merger Between Mylan and Pfizer's Upjohn Unit
The merger of Pfizer's (NYSE:PFE) generic drug business, Upjohn, with Mylan (NASDAQ:MYL) will be going through shortly, now that the companies have agreed to a consent . . .
Posted on 11/2/20
3 Reasons Pfizer and BioNTech's Coronavirus Vaccine Might Fail Even If It Works
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) are on the cusp of producing phase 3 data that could show their coronavirus vaccine, BNT162, protects participants from developing COVID-19 . . .
Posted on 11/2/20
Forget Moderna -- This Is A More Lucrative Coronavirus Stock
Moderna (NASDAQ:MRNA) is without a doubt one of the most talked about coronavirus stocks these days. The company was the first to launch its coronavirus vaccine . . .
Posted on 11/2/20
3 Reasons Vertex Is Still a Buy After Its Recent Pipeline Setback
Vertex Pharmaceuticals (NASDAQ:VRTX) reported its third-quarter results after the market closed on Thursday. Based on the stock's subsequent movement, you'd probably think the company announced a . . .
Posted on 11/2/20
3 Reasons to Buy Vertex Pharmaceuticals and 1 Reason Not To
Vertex Pharmaceuticals (NASDAQ:VRTX) is a pharmaceutical company that has utilized its portfolio of medicines for cystic fibrosis (CF) to grow consistently, expanding its trailing revenues by . . .
Posted on 11/2/20
5 Reasons to Buy Regeneron Stock and Never Sell
Regeneron Pharmaceuticals (NASDAQ:REGN) is arguably one of the best-performing biotech stocks of the past decade, with its shares up more than 2,050% since 2010, beating the . . .
Posted on 11/2/20
The 1 Reason Why Teladoc Health and Livongo Were So Eager to Merge
The coronavirus pandemic has driven demand for telehealth services to an all-time high, but the U.S. market leader isn't resting on its laurels. Shareholders of Teladoc . . .
Posted on 11/1/20
Dan MacDonald PT Joins Peak Physical Therapy & Sports Performance’s Pembroke Clinic
Peak Physical Therapy & Sports Performance, a South Shore practice specializing in unique programs that provide comprehensive
Posted on 11/1/20
Andreas Tomac Joins Holy Cross Health
Highly acclaimed neurosurgeon Andreas C. Tomac, M.D., Ph.D., F.A.A.N.S. has joined Holy Cross Medical Group
Posted on 10/30/20
Howard Hospital Foundation Names Tom McGuire to Board
Howard Hospital Foundation, which provides philanthropic support to Howard County General Hospital, named Tom McGuire to the board of trustees.
Posted on 10/30/20
Erbi Biosystems Closes $3.8 Million Financing
Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT, announced today the closing of a finance round which brings
Posted on 10/30/20
Dublin-based Start-up Launches Wirano Global Digital Platform for Clinical Trial Organization
A Dublin-based tech start-up today announced the launch of Wirano – a digital platform for the rapid and effective organization of clinical trials. The platform aims . . .
Posted on 10/30/20
Novan Reports Third Quarter 2020 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (Nasdaq: NOVN), today announced its financial results for the quarter ended September 30, 2020 and provided . . .
Posted on 10/30/20
Bristol Myers Squibb: The MyoKardia Acquisition Was Not A Bad Idea
SummaryMYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it.Indeed, . . .
Posted on 10/30/20
Moderna Expects First Look at Coronavirus Vaccine Candidate Data in November
Moderna (NASDAQ:MRNA) expects to take its first interim peek at data from the late-stage clinical trial of its coronavirus vaccine candidate, mRNA-1273, in November. Comments to . . .
Posted on 10/30/20
Emergent BioSolutions: Deep Value Play With 33% Upside & Military Exposure
SummaryEmergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats.They hold the only FDA approved anthrax vaccine . . .
Posted on 10/30/20
Novavax: Still Everything To Play For - Expect Plenty Of Data-Driven Volatility
SummaryNovavax has had to play second fiddle to Big Pharmas Pfizer, AstraZeneca, and Johnson & Johnson in recent months in the race to develop a COVID-19 . . .

